Tessa Angle Email

Director, RxMx Americas . RxMx

Current Roles

Employees:
98
Revenue:
$26.5M
About
Innovation Supporting Medicines RxMx uses systems innovation to re-engineer risk management strategies and patient support for medicines. With origins in Australia, RxMx also operates in the USA and Germany. Traditionally, medicine has been slow to adopt the scale of productivity improvements that other industries take for granted. Our platforms use automated technologies to bridge the gap between pharmaceuticals and real-world risk mitigation; deliver enhanced, efficient patient support programs; and to manage integrated patient reported outcome studies. Founded by four specialist physicians, our driving philosophy is developing medical systems that ensure the safe delivery of complex and sophisticated medicines, with minimal burden on physicians and patients. We offer healthcare organisations three programs that support the use of medicines: RiskMx platform for automated monitoring, alerting and RMP implementation Technology-enabled Patient Support Programs MOD (MObile Data) Patient Reported Outcomes (PRO) platform The RiskMx platform, developed and tested in a clinical trial, bridges the gap between pharmaceuticals and risk mitigation and is built for customisation to any medicine. At its heart, the RiskMx core continuously monitors pathology and other patient-level data using pre-defined algorithms that provide the basis for automated, real-time, healthcare practitioner-friendly REMS/RMP implementation. The MOD (MObile Data) platform is specifically designed to manage PRO studies. It provides a completely automated pipeline using web, SMS and email technologies to generate aggregated, cumulative trial datasets in real-time, without human intervention. Our smart-IT based PSP platform for RxMx Patient and Adherence Support programs complements high quality nursing, providing patient support for new and existing medicines.
RxMx Address

Sydney, null
AUS

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.